6.4 Summary of RCTs In the RIPENACTB trial, adjunct NAC treatment with 1,200 mg twice a day in hospitalized HIV/TB patients significantly reduced circulating lipid peroxidation (malondialdehyde (MDA) levels by approximately 40%50%) and increased antioxidant defenses, including glutathione (GSH, by approximately 30%40%), compared to baseline and the standard care group
Tranexamic Acid (TXA): A clinically recognized brightening active that interrupts melanin overproduction at the source, visibly reducing the appearance of stubborn dark spots, post-acne marks, and hyperpigmentation
DAC vs No-DAC: Whats the Difference
Notably, this performance was optimized through a controlled temperature gradient protocol (2530C for 6 h), which effectively mitigated proteotoxic stress-induced biomass loss from 45% to 12% while preserving extracellular PET hydrolase activity at 212.4 8.7 U/mg
Nature 475 , 324332 (2011)